Bacteria Immune Response Marketing 
Pharmaceutical Technology
MAY 25, 2023
The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK. for serogroup W to 20.5
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 4, 2020
Under the agreement Valneva could receive up to $308 million in cash payments, after Pfizer paid $130 million up front for marketing rights to the vaccine if it succeeds in the clinic. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.
XTalks
JULY 28, 2021
Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.
XTalks
JUNE 21, 2024
This is more than the approximately 52 percent covered by Pfizer’s Prevnar 20, which is the current pneumococcal vaccine market leader and the top player in the company’s pneumococcal vaccine portfolio. Pfizer’s Prevnar 20 was first approved in 2021 for adults 18 years of age and older and has since dominated the market.
pharmaphorum
JULY 14, 2021
Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.
pharmaphorum
APRIL 26, 2022
With more research being published, there has arrived greater interest in how individual microbiomes could influence health and there is now a growing market of prebiotic, probiotic and postbiotic commercial products based on the links being made to various health conditions. Compelling advantages.
Expert insights. Personalized for you.
195 
Let's personalize your content